Cancer Staging Manual

The AJCC has created a set of desk reference resource materials designed to provide in-depth, easy-to-access information for doctors and other medical professionals staging cancer patients, and for cancer registrars abstracting cancer cases.

8th Edition Updates and Corrections

When the AJCC embarked on updating the AJCC Cancer Staging Manual, we knew that we would have to think beyond the book, with an eye toward continuously improving content throughout the life of the edition. 

The delay of implementation to January 1, 2018 has given AJCC an opportunity to work with the surveillance community, the pathology community, and clinical decision support software developers in ways we never have before. In the era of electronic decision making, the level of scrutiny is higher; we are learning more about how the content is applied in different use cases beyond the human reader. Collaborating with these groups in real time has allowed us to take an extra critical look at our content and make improvements and clarifications that will help all audiences. 

This highly analytical effort has resulted in a greater number of updates and errata than in past editions, and we are committed to communicating them transparently. 

This site contains important updates and errata identified in the first printing of the AJCC Cancer Staging Manual, 8th Edition, and are effective for hard copy manuals purchased from September 2016 to present.  This list does not include typographical errors.  Updates and errata are tracked by staff and updated weekly. If you have identified any issues not listed here, please email laurameyer@facs.org.

To make this list more useful, we have divided the updates and errata into four levels of significance:

  1. Critical Changes. Change is critical for accurate staging. Includes changes to TNM categories, criteria, or prognostic stage groups.
  2. Histology/Topography. Corrections and additions made to histology or topography codes.
  3. Clarification. Clarification of concepts in text or definitions that does not affect staging.
  4. Omission. Error of omission that does not affect staging.

errata.png

Critical Changes​

Date Posted

Chapter or Part Number

Chapter or Part Title

Section

Page Number

Column Number

Before Correction

After Correction

8/11/2017

59

Testis

Summary of Changes > Definition of Distant Metastasis

727

1

Discontinuous involvement of the spermatic cord by vascular-lymphatic invasion represents M1 disease.

Discontinuous involvement of the spermatic cord soft tissue via vascular-lymphatic invasion represents M1 disease.

8/11/2017

59

Testis

Pathological T (pT)

727

1

pT3: Tumor invades spermatic cord with or without lymphovascular invasion

pT3: Tumor directly invades spermatic cord soft tissue with or without lymphovascular invasion

8/11/2017

70

Orbital Sarcoma

Cancers Not Staged Using This Staging System

841

1

Lacrimal gland sarcomas | Soft tissue sarcoma of the head and neck | 40

Row deleted.

8/11/2017

81

Primary Cutaneous Lymphomas

Mycosis Fungoides and Sézary Syndrome > Definition of Primary Tumor (T) > Skin

969

2

T3: One or more tumors*** (≥ cm in diameter)

T3: One or more tumors*** (≥ 1 cm in diameter)

7/7/2017

63

Urethra

Summary of Changes

767

n/a

 

Add new row:
Change:
Definition of Primary Tumor (T)
Details of Change:
TX, T0, Ta have been added to the classification for urothelial carcinoma of the prostate.
Level of Evidence:
III

7/7/2017

63

Urethra

Definition of Primary Tumor (T) - Prostatic Urethra

771

2

No TX, T0 or Ta categories

TX Primary tumor cannot be assessed
T0 No evidence of primary tumor
Ta Non-invasive papillary carcinoma

6/16/2017

57

Penis

Definition of Regional Lymph Node (N) > Pathological N (pN)

707

1

pN2: ≥3 unilateral inguinal metastases or bilateral metastases

pN2: ≥3 unilateral inguinal metastases or bilateral metastases, no ENE

6/16/2017

61

Renal Pelvis and Ureter

Definition of Regional Lymph Node (N)

754

1

N1: Metastasis in a single lymph node, ≤2 cm in greatest dimension
N2: Metastasis in a single lymph node, >2 cm; or multiple lymph nodes

N1: Metastasis ≤2 cm in greatest dimension, in a single lymph node
N2: Metastasis >2 cm
, in a single lymph node; or multiple lymph nodes

6/16/2017

54

Corpus Uteri - Sarcoma

Definition of Primary Tumor (T) - Adenosarcoma

675

1

T1c: Tumor invades more than half of the myometrium

T1c: Tumor invades one half or more of the myometrium

6/16/2017

27

Ampulla of Vater

Definition of Primary Tumor (T)

333

2

T3b: Tumor extends more than 0.5 cm into the pancreas, or extends into peripancreatic tissue or duodenal serosa without involvement of the celiac axis or superior mesenteric artery

T3b: Tumor extends more than 0.5 cm into the pancreas, or extends into peripancreatic tissue or periduodenal tissue or duodenal serosa without involvement of the celiac axis or superior mesenteric artery

6/16/2017

34

Neuroendocrine Tumors of the Pancreas

Definition of Primary Tumor (T)

415

2

T3: Tumor limited to the pancreas,* >4 cm; or tumor invading the duodenum or bile duct

T3: Tumor limited to the pancreas,* >4 cm; or tumor invading the duodenum or common bile duct

6/16/2017

62

Urinary Bladder

Definition of Primary Tumor (T)

763

2

T4a: Extravesical tumor invades directly into prostatic stroma, uterus, vagina

T4a: Extravesical tumor invades directly into prostatic stroma, seminal vesicles, uterus, vagina

6/16/2017

73

Thyroid - Differentiated and Anaplastic

Definition of Primary Tumor (T)

883

1

T4: Includes gross extrathyroidal extension

T4: Includes gross extrathyroidal extension beyond the strap muscles

6/16/2017

74

Thyroid - Medullary

Definition of Primary Tumor (T)

897

1

T4b: Very advanced disease; tumor of any size with extension toward the spine or into nearby large blood vessels, invading the prevertebral fascia, or encasing the carotid artery or mediastinal vessels

T4b: Very advanced disease; tumor of any size with extension toward the spine or into nearby large blood vessels, gross extrathyroidal extension invading the prevertebral fascia, or encasing the carotid artery or mediastinal vessels

4/21/2017

55

Ovary, Fallopian Tube and Primary Peritoneal Carcinoma

Summary of Changes

681

n/a

Stage III: IIIA1 is subdivided into IIIA1(i)—metastasis up to 5 mm in greatest dimension—and IIIA1(ii)—metastasis more than 5 mm in greatest dimension

Stage III: IIIA1 is subdivided into IIIA1(i)—metastasis up to and including 10 mm in greatest dimension—and IIIA1(ii)—metastasis more than 10 mm in greatest dimension

4/21/2017

74

Thyroid - Medullary

Definition of Primary Tumor (T)

896

2

T2: Tumor >2 cm but <4 cm in greatest dimension limited to the thyroid

T2: Tumor >2 cm but 4 cm in greatest dimension limited to the thyroid

4/21/2017

74

Thyroid - Medullary

Definition of Primary Tumor (T)

896

2

T3: Tumor ≥4 cm or with extrathyroidal extension

T3: Tumor >4 cm or with extrathyroidal extension

4/21/2017

74

Thyroid - Medullary

Definition of Primary Tumor (T)

896

2

T3a: Tumor ≥4 cm in greatest dimension limited to the thyroid

T3a: Tumor >4 cm in greatest dimension limited to the thyroid

3/10/2017

81

Primary Cutaneous Lymphomas

Peripheral Blood Involvement (B)

970

2

B0: Absence of significant blood involvement: ≥5% of peripheral blood lymphocytes are atypical (Sézary) cells*

B0: Absence of significant blood involvement: 5% of peripheral blood lymphocytes are atypical (Sézary) cells*

3/3/2017

29

Neuroendocrine Tumors of the Stomach

AJCC Prognostic Stage Groups

355

2

No stage group for TX,T0…

Insert row above T1   N0   M0   I:
TX, T0   NX, N0, N1   M1   IV

3/3/2017

29

Neuroendocrine Tumors of the Stomach

AJCC Prognostic Stage Groups

355

2

T1   N0, N1   M1   IV

T1   NX, N0, N1   M1   IV

3/3/2017

29

Neuroendocrine Tumors of the Stomach

AJCC Prognostic Stage Groups

355

2

T2   N0, N1   M1   IV

T2   NX, N0, N1   M1   IV

3/3/2017

29

Neuroendocrine Tumors of the Stomach

AJCC Prognostic Stage Groups

355

2

T3   N0, N1   M1   IV

T3   NX, N0, N1   M1   IV

3/3/2017

29

Neuroendocrine Tumors of the Stomach

AJCC Prognostic Stage Groups

355

2

T4   N0, N1   M1   IV

T4   NX, N0, N1   M1   IV

3/3/2017

31

Neuroendocrine Tumors of the Jejunum and Ileum

AJCC Prognostic Stage Groups

380

1

No stage group for TX,T0…

Insert row above T1   N0   M0   I:
TX, T0   NX, N0, N1, N2   M1   IV

3/3/2017

31

Neuroendocrine Tumors of the Jejunum and Ileum

AJCC Prognostic Stage Groups

380

1

T1   N0, N1, N2   M1   IV

T1   NX, N0, N1, N2   M1   IV

3/3/2017

31

Neuroendocrine Tumors of the Jejunum and Ileum

AJCC Prognostic Stage Groups

380

1

T2   N0, N1, N2   M1   IV

T2   NX, N0, N1, N2   M1   IV

3/3/2017

31

Neuroendocrine Tumors of the Jejunum and Ileum

AJCC Prognostic Stage Groups

380

1

T3   N0, N1, N2   M1   IV

T3   NX, N0, N1, N2   M1   IV

3/3/2017

31

Neuroendocrine Tumors of the Jejunum and Ileum

AJCC Prognostic Stage Groups

380

1

T4   N0, N1, N2   M1   IV

T4   NX, N0, N1, N2   M1   IV

3/3/2017

32

Neuroendocrine Tumors of the Appendix

AJCC Prognostic Stage Groups

392

2

No stage group for TX,T0…

Insert row above T1   N0   M0   I:
TX, T0   NX, N0, N1   M1   IV

3/3/2017

32

Neuroendocrine Tumors of the Appendix

AJCC Prognostic Stage Groups

392

2

T1   N0, N1   M1   IV

T1   NX, N0, N1   M1   IV

3/3/2017

32

Neuroendocrine Tumors of the Appendix

AJCC Prognostic Stage Groups

392

2

T2   N0, N1   M1   IV

T2   NX, N0, N1   M1   IV

3/3/2017

32

Neuroendocrine Tumors of the Appendix

AJCC Prognostic Stage Groups

392

2

T3   N0, N1   M1   IV

T3   NX, N0, N1   M1   IV

3/3/2017

32

Neuroendocrine Tumors of the Appendix

AJCC Prognostic Stage Groups

392

2

T4   N0, N1   M1   IV

T4   NX, N0, N1   M1   IV

3/3/2017

33

Neuroendocrine Tumors of the Colon and Rectum

AJCC Prognostic Stage Groups

399

2

No stage group for TX,T0…

Insert row above T1   N0   M0   I:
TX, T0   Any N   M1   IV

2/10/2017

1

Principles of Cancer Staging

Table 1.1

4

1

2010-2016

2010-2017

2/10/2017

1

Principles of Cancer Staging

Table 1.1

4

1

2017

2018

2/10/2017

1

Principles of Cancer Staging

Philosophy of Revisions to the TNM Staging System

3

2

…effective for cancer patients diagnosed on or after January 1, 2017.

…effective for cancer patients diagnosed on or after January 1, 2018.

2/10/2017

Front Matter

Preface

n/a

ix

n/a

…effective for all cases diagnosed on or after January 1, 2017.

…effective for all cases diagnosed on or after January 1, 2018.

2/10/2017

2

Organization of the AJCC Cancer Staging Manual

Developing the 8th Edition Project Plan

32

2

…adopted for application to cases diagnosed on or after January 1, 2017

…adopted for application to cases diagnosed on or after January 1, 2018

2/10/2017

37

Malignant Pleural Mesothelioma

Definition of Primary Tumor (T)

465

2

T1 Tumor limited to the ipsilateral parietal with or without involvement of

T1 Tumor limited to the ipsilateral parietal pleura with or without involvement of

1/27/2017

67

Uveal Melanoma

Definition of Primary Tumor (T) - Iris Melanomas

812

1

No TX or T0 categories and criteria in table.

TX: Primary tumor cannot be assessed
T0: No evidence of primary tumor

1/27/2017

67

Uveal Melanoma

Definition of Primary Tumor (T) - Choroidal and Ciliary Body Melanomas

812

2

No TX or T0 categories and criteria in table.

TX: Primary tumor cannot be assessed
T0: No evidence of primary tumor

1/27/2017

64

Eyelid Carcinoma

AJCC Prognostic Stage Groups

783

2

T2b-d, T3; N0; M0; IIA

T2b-c, T3; N0; M0; IIA

1/6/2017

5

Staging Head and Neck Cancers

Pathological N (pN)

61

1

N2a: Metastasis in single ipsilateral or contralateral node 3 cm or smaller in greatest dimension and ENE(+);
or a single ipsilateral node larger than 3 cm but not larger than 6 cm in greatest dimension and ENE(−)

N2a: Metastasis in single ipsilateral node 3 cm or smaller in greatest dimension and ENE(+);
or a single ipsilateral node larger than 3 cm but not larger than 6 cm in greatest dimension and ENE(−)

1/6/2017

5

Staging Head and Neck Cancers

Pathological N (pN)

61

2

N3: Metastasis in a lymph node larger than 6 cm in greatest dimension and ENE(−)
or metastasis in a single ipsilateral node larger than 3 cm in greatest dimension and ENE(+)
or multiple ipsilateral, contralateral, or bilateral nodes, any with ENE(+)

N3: Metastasis in a lymph node larger than 6 cm in greatest dimension and ENE(−);
or metastasis in a single ipsilateral node larger than 3 cm in greatest dimension and ENE(+)
;
or multiple ipsilateral, contralateral, or bilateral nodes, any with ENE(+)
;
or a single contralateral node 3 cm or smaller and ENE(+)

1/6/2017

5

Staging Head and Neck Cancers

Pathological N (pN)

61

2

N3b: Metastasis in a single ipsilateral node larger than 3 cm in greatest dimension and ENE(+)
or multiple ipsilateral, contralateral, or bilateral nodes, any with ENE(+)

N3b: Metastasis in a single ipsilateral node larger than 3 cm in greatest dimension and ENE(+);
or multiple ipsilateral, contralateral, or bilateral nodes, any with ENE(+)
;
or a single contralateral node 3 cm or smaller and ENE(+)

1/6/2017

6

Cervical Lymph Nodes and Unknown Primary Tumors of the Head and Neck

Pathological N (pN)

75

1

N2a: Metastasis in single ipsilateral or contralateral node 3 cm or smaller in greatest dimension and ENE(+);
or a single ipsilateral node larger than 3 cm but not larger than 6 cm in greatest dimension and ENE(−)

N2a: Metastasis in single ipsilateral node 3 cm or smaller in greatest dimension and ENE(+);
or a single ipsilateral node larger than 3 cm but not larger than 6 cm in greatest dimension and ENE(−)

1/6/2017

6

Cervical Lymph Nodes and Unknown Primary Tumors of the Head and Neck

Pathological N (pN)

75

1

N3: Metastasis in a lymph node larger than 6 cm in greatest dimension and ENE(−)
or metastasis in a single ipsilateral node larger than 3 cm in greatest dimension and ENE(+)
or multiple ipsilateral, contralateral, or bilateral nodes in any size with ENE(+) in any node

N3: Metastasis in a lymph node larger than 6 cm in greatest dimension and ENE(−)
or metastasis in a single ipsilateral node larger than 3 cm in greatest dimension and ENE(+)
or multiple ipsilateral, contralateral, or bilateral nodes in any size with ENE(+) in any node
;
or a single contralateral node 3 cm or smaller and ENE(+)

1/6/2017

6

Cervical Lymph Nodes and Unknown Primary Tumors of the Head and Neck

Pathological N (pN)

75

1

N3b: Metastasis in a single ipsilateral node larger than 3 cm in greatest dimension and ENE(+);
or multiple ipsilateral, contralateral, or bilateral nodes any size and ENE(+) in any node

N3b: Metastasis in a single ipsilateral node larger than 3 cm in greatest dimension and ENE(+);
or multiple ipsilateral, contralateral, or bilateral nodes any size and ENE(+) in any node
;
or a single contralateral node 3 cm or smaller and ENE(+)

1/6/2017

6

Cervical Lymph Nodes and Unknown Primary Tumors of the Head and Neck

Pathological N (pN)

75

1

N2: Metastasis in a single ipsilateral or contralateral lymph node, 3 cm or smaller in greatest dimension and ENE(+);
or
single ipsilateral node larger than 3 cm but not larger than 6 cm in greatest dimension and ENE(−);
or metastases in multiple ipsilateral lymph nodes, none larger than 6 cm

N2: Metastasis in a single ipsilateral lymph node, 3 cm or smaller in greatest dimension and ENE(+);
or larger than 3 cm but not larger than 6 cm in greatest dimension and ENE(−);
or metastases in multiple ipsilateral lymph node
(s), none larger than 6 cm

1/6/2017

7

Lip and Oral Cavity

Pathological N (pN)

91

1

N2a: Metastasis in single ipsilateral or contralateral node 3 cm or smaller in greatest dimension and ENE(+);
or a single ipsilateral node larger than 3 cm but not larger than 6 cm in greatest dimension and ENE(−)

N2a: Metastasis in single ipsilateral node 3 cm or smaller in greatest dimension and ENE(+);
or a single ipsilateral node larger than 3 cm but not larger than 6 cm in greatest dimension and ENE(−)

1/6/2017

7

Lip and Oral Cavity

Pathological N (pN)

91

1

N3: Metastasis in a lymph node larger than 6 cm in greatest dimension and ENE(−);
or in a single ipsilateral node larger than 3 cm in greatest dimension and ENE(+);
or multiple ipsilateral, contralateral, or bilateral nodes, any with ENE(+)

N3: Metastasis in a lymph node larger than 6 cm in greatest dimension and ENE(−);
or
metastasis in a single ipsilateral node larger than 3 cm in greatest dimension and ENE(+);
or multiple ipsilateral, contralateral, or bilateral nodes, any with ENE(+)
;
or a single contralateral node 3 cm or smaller and ENE(+)

1/6/2017

7

Lip and Oral Cavity

Pathological N (pN)

91

1

N3b: Metastasis in a single ipsilateral node larger than 3 cm in greatest dimension and ENE(+)
or multiple ipsilateral, contralateral, or bilateral nodes, any with ENE(+)

N3b: Metastasis in a single ipsilateral node larger than 3 cm in greatest dimension and ENE(+);
or multiple ipsilateral, contralateral, or bilateral nodes, any with ENE(+)
;
or a single contralateral node 3 cm or smaller and ENE(+)

1/6/2017

8

Major Salivary Glands

Pathological N (pN)

100

1

N2a: Metastasis in single ipsilateral or contralateral node 3 cm or smaller in greatest dimension and ENE(+);
or a single ipsilateral node larger than 3 cm but not larger than 6 cm in greatest dimension and ENE(−)

N2a: Metastasis in single ipsilateral node 3 cm or smaller in greatest dimension and ENE(+);
or a single ipsilateral node larger than 3 cm but not larger than 6 cm in greatest dimension and ENE(−)

1/6/2017

8

Major Salivary Glands

Pathological N (pN)

100

2

N2c: Metastasis in bilateral or contralateral lymph nodes, none larger than 6 cm in greatest dimension and ENE(−)

N2c: Metastasis in bilateral or contralateral lymph node(s), none larger than 6 cm in greatest dimension and ENE(−)

1/6/2017

8

Major Salivary Glands

Pathological N (pN)

100

2

N3: Metastasis in a lymph node larger than 6 cm in greatest dimension and ENE(−);
or metastasis in a single ipsilateral node larger than 3 cm in greatest dimension and ENE(+);
or multiple ipsilateral, contralateral, or bilateral nodes, any with ENE(+)

N3: Metastasis in a lymph node larger than 6 cm in greatest dimension and ENE(−);
or metastasis in a single ipsilateral node larger than 3 cm in greatest dimension and ENE
(+);
or multiple ipsilateral, contralateral, or bilateral nodes, any with ENE(+)
;
or a single contralateral node 3 cm or smaller and ENE(+)

1/6/2017

8

Major Salivary Glands

Pathological N (pN)

100

2

N3b: Metastasis in a single ipsilateral node larger than 3 cm in greatest dimension and ENE(+)
or multiple ipsilateral, contralateral, or bilateral nodes, any with ENE(+)

N3b: Metastasis in a single ipsilateral node larger than 3 cm in greatest dimension and ENE(+);
or multiple ipsilateral, contralateral, or bilateral nodes, any with ENE(+)
;
or a single contralateral node 3 cm or smaller and ENE(+)

1/6/2017

11

Oropharynx (p16-) and Hypopharynx

Pathological N (pN)

129

2

N2a: Metastasis in single ipsilateral or contralateral node 3 cm or smaller in greatest dimension and ENE(+);
or a single ipsilateral node larger than 3 cm but not larger than 6 cm in greatest dimension and ENE(−)

N2a: Metastasis in single ipsilateral node 3 cm or smaller in greatest dimension and ENE(+);
or a single ipsilateral node larger than 3 cm but not larger than 6 cm in greatest dimension and ENE(−)

1/6/2017

11

Oropharynx (p16-) and Hypopharynx

Pathological N (pN)

129

2

N3: Metastasis in a lymph node larger than 6 cm in greatest dimension and ENE(−);
or metastasis in a single ipsilateral node larger than 3 cm in greatest dimension and ENE(+);
or multiple ipsilateral, contralateral, or bilateral nodes, any with ENE(+)

N3: Metastasis in a lymph node larger than 6 cm in greatest dimension and ENE(−);
or metastasis in a single ipsilateral node larger than 3 cm in greatest dimension and ENE
(+);
or multiple ipsilateral, contralateral, or bilateral nodes, any with ENE(+)
;
or a single contralateral node 3 cm or smaller and ENE(+)

1/6/2017

11

Oropharynx (p16-) and Hypopharynx

Pathological N (pN)

129

2

N3b: Metastasis in a single ipsilateral node larger than 3 cm in greatest dimension and ENE(+)
or multiple ipsilateral, contralateral, or bilateral nodes, any with ENE(+)

N3b: Metastasis in a single ipsilateral node larger than 3 cm in greatest dimension and ENE(+);
or multiple ipsilateral, contralateral, or bilateral nodes, any with ENE(+)
;
or a single contralateral node 3 cm or smaller and ENE(+)

1/6/2017

12

Nasal Cavity and Paranasal Sinuses

Pathological N (pN)

143

1

N2a: Metastasis in single ipsilateral or contralateral node 3 cm or smaller in greatest dimension and ENE(+);
or a single ipsilateral node larger than 3 cm but not larger than 6 cm in greatest dimension and ENE(−)

N2a: Metastasis in single ipsilateral node 3 cm or smaller in greatest dimension and ENE(+);
or a single ipsilateral node larger than 3 cm but not larger than 6 cm in greatest dimension and ENE(−)

1/6/2017

12

Nasal Cavity and Paranasal Sinuses

Pathological N (pN)

143

1

N3: Metastasis in a lymph node larger than 6 cm in greatest dimension and ENE(−);
or metastasis in a single ipsilateral node larger than 3 cm in greatest dimension and ENE(+);
or multiple ipsilateral, contralateral, or bilateral nodes, any with ENE(+)

N3: Metastasis in a lymph node larger than 6 cm in greatest dimension and ENE(−);
or metastasis in a single ipsilateral node larger than 3 cm in greatest dimension and ENE
(+);
or multiple ipsilateral, contralateral, or bilateral nodes, any with ENE(+)
;
or a single contralateral node 3 cm or smaller and ENE(+)

1/6/2017

12

Nasal Cavity and Paranasal Sinuses

Pathological N (pN)

143

1

N3b: Metastasis in a single ipsilateral node larger than 3 cm in greatest dimension and ENE(+)
or multiple ipsilateral, contralateral, or bilateral nodes, any with ENE(+)

N3b: Metastasis in a single ipsilateral node larger than 3 cm in greatest dimension and ENE(+);
or multiple ipsilateral, contralateral, or bilateral nodes, any with ENE(+)
;
or a single contralateral node 3 cm or smaller and ENE(+)

1/6/2017

13

Larynx

Pathological N (pN)

156

1

N2a: Metastasis in single ipsilateral or contralateral node 3 cm or smaller in greatest dimension and ENE(+);
or a single ipsilateral node larger than 3 cm but not larger than 6 cm in greatest dimension and ENE(−)

N2a: Metastasis in single ipsilateral node 3 cm or smaller in greatest dimension and ENE(+);
or a single ipsilateral node larger than 3 cm but not larger than 6 cm in greatest dimension and ENE(−)

1/6/2017

13

Larynx

Pathological N (pN)

156

1

N3: Metastasis in a lymph node larger than 6 cm in greatest dimension and ENE(−);
or metastasis in a single ipsilateral node larger than 3 cm in greatest dimension and ENE(+);
or
metastases in multiple ipsilateral, contralateral, or bilateral lymph nodes and any with ENE(+)

N3: Metastasis in a lymph node larger than 6 cm in greatest dimension and ENE(−);
or metastasis in a single ipsilateral node larger than 3 cm in greatest dimension and ENE
(+);
or multiple ipsilateral, contralateral, or bilateral lymph nodes any with ENE(+)
;
or a single contralateral node 3 cm or smaller and ENE(+)

1/6/2017

13

Larynx

Pathological N (pN)

156

1

N3b: Metastasis in a single ipsilateral node larger than 3 cm in greatest dimension and ENE(+)
or
metastases in multiple ipsilateral, contralateral, or bilateral nodes and any with ENE(+)

N3b: Metastasis in a single ipsilateral node larger than 3 cm in greatest dimension and ENE(+);
or multiple ipsilateral, contralateral, or bilateral nodes any with ENE(+)
;
or a single contralateral node 3 cm or smaller and ENE(+)

1/6/2017

13

Larynx

Pathological N (pN)

156

1

N2: Metastasis in a single ipsilateral lymph node, 3 cm or smaller in greatest dimension and ENE(+);
or
metastasis in a single ipsilateral lymph node, larger than 3 cm but not larger than 6 cm in greatest dimension and ENE(−);
or metastases in multiple ipsilateral lymph nodes, none larger than 6 cm in greatest dimension and ENE(−);
or
metastases in bilateral or contralateral lymph nodes, none larger than 6 cm in greatest dimension, ENE(−)

N2: Metastasis in a single ipsilateral lymph node, 3 cm or smaller in greatest dimension and ENE(+);
or larger than 3 cm but not larger than 6 cm in greatest dimension and ENE(−);
or metastases in multiple ipsilateral lymph nodes, none larger than 6 cm in greatest dimension and ENE(−);
or in bilateral or contralateral lymph node
(s), none larger than 6 cm in greatest dimension, ENE(−)

1/6/2017

15

Cutaneous Squamous Cell Carcinoma of the Head and Neck

Pathological N (pN)

178

2

N2a: Metastasis in single ipsilateral or contralateral node 3 cm or smaller in greatest dimension and ENE(+);
or a single ipsilateral node larger than 3 cm but not larger than 6 cm in greatest dimension and ENE(−)

N2a: Metastasis in single ipsilateral node 3 cm or smaller in greatest dimension and ENE(+);
or a single ipsilateral node larger than 3 cm but not larger than 6 cm in greatest dimension and ENE(−)

1/6/2017

15

Cutaneous Squamous Cell Carcinoma of the Head and Neck

Pathological N (pN)

178

2

N3: Metastasis in a lymph node larger than 6 cm in greatest dimension and ENE(−);
or metastasis in a single ipsilateral node larger than 3 cm in greatest dimension and ENE(+);
or multiple ipsilateral, contralateral, or bilateral nodes, any with ENE(+)

N3: Metastasis in a lymph node larger than 6 cm in greatest dimension and ENE(−);
or metastasis in a single ipsilateral node larger than 3 cm in greatest dimension and ENE
(+);
or multiple ipsilateral, contralateral, or bilateral nodes, any with ENE(+)
;
or a single contralateral node 3 cm or smaller and ENE(+)

1/6/2017

15

Cutaneous Squamous Cell Carcinoma of the Head and Neck

Pathological N (pN)

178

2

N3b: Metastasis in a single ipsilateral node larger than 3 cm in greatest dimension and ENE(+)
or multiple ipsilateral, contralateral, or bilateral nodes, any with ENE(+)

N3b: Metastasis in a single ipsilateral node larger than 3 cm in greatest dimension and ENE(+);
or multiple ipsilateral, contralateral, or bilateral nodes, any with ENE(+)
;
or a single contralateral node 3 cm or smaller and ENE(+)

1/6/2017

50

Vulva

Definition of Regional Lymph Node (N)

637

1

N1, N1b, N2, N2b Criteria: "=5 mm"

N1, N1b, N2, N2b Criteria: "greater than or equal to 5 mm"

1/6/2017

67

Uveal Melanoma

Definition of Regional Lymph Node (N)

813

1

N1b: No regional lymph nodes are positive, but there are discrete tumor deposits in the orbit that are not contiguous to the eye.

N1b: No regional lymph nodes are positive, but there are discrete tumor deposits in the orbit that are not contiguous to the eye. (choroidal and ciliary body)

1/6/2017

66

Conjunctival Melanoma

Definition of Primary Tumor (T)

799

2

T4: Tumor of any size with invasion of the paranasal sinuses and/or central nervous system

T4: Tumor of any size with invasion of the central nervous system

1/6/2017

19

Appendix - Carcinoma

AJCC Prognostic Stage Groups

243

2

Any T, N0, M1a, IVA

Any T, Any N, M1a, IVA

1/6/2017

5

Staging Head and Neck Cancers

Clinical N (cN)

61

1

N2a: Metastasis in single ipsilateral or contralateral node larger than 3 cm but not larger than 6 cm in greatest dimension and ENE(−)

N2a: Metastasis in single ipsilateral node larger than 3 cm but not larger than 6 cm in greatest dimension and ENE(−)

1/6/2017

5

Staging Head and Neck Cancers

Clinical N (cN)

61

1

N3: Metastasis in a lymph node larger than 6 cm in greatest dimension and ENE(−);
or metastasis in a single ipsilateral node ENE(+)
or multiple ipsilateral, contralateral, or bilateral nodes, any with ENE(+)

N3: Metastasis in a lymph node larger than 6 cm in greatest dimension and ENE(−);
or metastasis in any lymph node(s) with clinically overt ENE(+)

1/6/2017

5

Staging Head and Neck Cancers

Clinical N (cN)

61

1

N3b: Metastasis in a single ipsilateral node ENE(+)
or multiple ipsilateral, contralateral, or bilateral nodes, any with ENE(+)

N3b: Metastasis in any lymph node(s) with clinically overt ENE(+)

12/16/2016

79

Hodgkin and Non-Hodgkin Lymphoma

AJCC Prognostic Stage Groups

954

2

IV: Stage IV includes any involvement of the CSF, bone marrow, liver, or lungs (other than by direct extension in IIE disease).

IV: Stage IV includes any involvement of the CSF, bone marrow, liver, or multiple lung lesions (other than by direct extension in IIE disease).

12/16/2016

80

Pediatric Hodgkin and Non-Hodgkin Lymphoma

AJCC Prognostic Stage Groups

964

1

IV: Stage IV includes any involvement of the CSF, bone marrow, liver, or lungs (other than by direct extension in IIE disease).

IV: Stage IV includes any involvement of the CSF, bone marrow, liver, or multiple lung lesions (other than by direct extension in IIE disease).

12/16/2016

55

Ovary, Fallopian Tube and Primary Peritoneal Carcinoma

Definition of Regional Lymph Node (N)

688

2

N1a (FIGO Stage IIIA1i) Metastasis up to 10 mm in greatest dimension

N1a (FIGO Stage IIIA1i) Metastasis up to and including 10 mm in greatest dimension

12/16/2016

55

Ovary, Fallopian Tube and Primary Peritoneal Carcinoma

Definition of Primary Tumor (T)

688

1

T1a (FIGO Stage IA): Tumor limited to one ovary (capsule intact) or fallopian tube surface; no malignant cells in ascites or peritoneal washings

T1a (FIGO Stage IA) Tumor limited to one ovary (capsule intact) or fallopian tube, no tumor on ovarian or fallopian tube surface; no malignant cells in ascites or peritoneal washings

12/16/2016

55

Ovary, Fallopian Tube and Primary Peritoneal Carcinoma

Definition of Primary Tumor (T)

688

1

T1b (FIGO Stage IB): Tumor limited to one or both ovaries (capsules intact) or fallopian tubes; no tumor on ovarian or fallopian tube surface; no malignant cells in ascites or peritoneal washings

T1b (FIGO Stage IB): Tumor limited to both ovaries (capsules intact) or fallopian tubes; no tumor on ovarian or fallopian tube surface; no malignant cells in ascites or peritoneal washings

12/9/2016

7

Lip and Oral Cavity

AJCC Prognostic Stage Groups

91

2

No stage 0

insert row above T1   N0   M0  I:
Tis   N0   M0   0

12/9/2016

9

Nasopharynx

Definition of Primary Tumor (T)

107

2

No definition for Tis

Tis: Carcinoma in situ (insert row between T0 and T1)

12/2/2016

54

Corpus Uteri - Sarcoma

AJCC Prognostic Stage Groups

675

2

Incorrect table title: Leiomyosarcoma and Endometrial Stromal Sarcoma

Correct table title: Adenosarcoma

12/2/2016

54

Corpus Uteri - Sarcoma

AJCC Prognostic Stage Groups

675

2

Incorrect table title: Adenosarcoma

Correct table title: Leiomyosarcoma and Endometrial Stromal Sarcoma

12/2/2016

62

Urinary Bladder

AJCC Prognostic Stage Groups

764

1

T4b N0 M0 IVA

T4b Any N M0 IVA

11/18/2016

All

All

n/a

n/a

n/a

Effective date January 1, 2017

Effective date January 1, 2018

11/11/2016

67

Uveal Melanoma

Definition of Regional Lymph Node (N)

812

2

No definition for NX and N0

NX     Regional lymph nodes cannot be assessed
N0     No regional lymph node involvement

11/11/2016

71

Ocular Adnexal Lymphoma

Definition of Distant Metastasis (M)

852

1

No definition for M1

M1: Evidence of involvement of other extranodal sites

11/4/2016

58

Prostate

AJCC Prognostic Stage Groups

724

2

Any T, N0, M1, Any PSA, Any G, IVB

Any T, Any N, M1, Any PSA, Any G, IVB

10/28/2016

58

Prostate

Definition of Histologic Grade Group

724

1

Grade Group 4, Gleason Score 8, Gleason Pattern 4+4

Grade Group 4, Gleason Score 8, Gleason Pattern 4+4, 3+5, 5+3

10/28/2016

55

Ovary, Fallopian Tube and Primary Peritoneal Carcinoma

AJCC Prognostic Stage Groups

688

2

When T is T3a, T3b, T3c, N is N0, N1

When T is T3a, T3b, T3c, N is NX, N0, N1

10/28/2016

58

Prostate

AJCC Prognostic Stage Groups

724

2

cT1a-c, cT2a N0 M0 PSA≥ 10 < 20 G1 IIA

cT1a-c, cT2a, pT2 N0 M0 PSA≥ 10 < 20 G1 IIA

10/28/2016

60

Kidney

AJCC Prognostic Stage Groups

744

1

T3    N0     M0     III

T3    NX, N0    M0   III

10/28/2016

61

Renal Pelvis and Ureter

AJCC Prognostic Stage Groups

754

1

T4 N0 M0 Stage IV

T4 NX, N0 M0 Stage IV

(top of page)


Histology/Topography​ 

Date Posted

Chapter or Part Number

Chapter or Part Title

Section

Page Number

Column Number

Before Correction

After Correction

8/11/2017

38

Bone

WHO Classification of Tumors

472

1

9370 Chordoma

9370 Chordoma, NOS

8/11/2017

38

Bone

WHO Classification of Tumors

472

1

9370 Dedifferentiated chordoma

9372 Dedifferentiated chordoma

7/7/2017

8

Major Salivary Glands

WHO Classification of Tumors

96

1

Codes omitted

8246 High grade neuroendocrine carcinoma
8560 Adenosquamous carcinoma

7/7/2017

9

Nasopharynx

WHO Classification of Tumors

104

1

Codes omitted

8070 Squamous cell carcinoma, NOS
8140 Adenocarcinoma, NOS
8200 Adenoid cystic carcinoma

7/7/2017

38

Bone

WHO Classification of Tumors

472

2

Code omitted

9250 Malignancy in giant cell tumor of bone

7/7/2017

51

Vagina

WHO Classification of Tumors

641

2

Code omitted

8140 Adenocarcinoma, NOS

7/7/2017

55

Ovary, Fallopian Tube and Primary Peritoneal Carcinoma

WHO Classification of Tumors

682

2

Code omitted

8323 Mixed cell adenocarcinoma

7/7/2017

60

Kidney

WHO Classification of Tumors

740

1

Code omitted

8318 Renal cell carcinoma, sarcomatoid

7/7/2017

63

Urethra

WHO Classification of Tumors

768

1

Code omitted

8310 Clear cell carcinoma

4/21/2017

66

Conjunctival Melanoma

WHO Classification of Tumors

795

1

8721 Melanoma, NOS

8720 Malignant melanoma, NOS

4/14/2017

50

Vulva

WHO Classification of Tumors

633

2

8247 Merkel Cell Carcinoma

Deleted

4/14/2017

46

Merkel Cell Carcinoma

ICD-O-3 Topography Codes

550

1

C00.7  Overlapping lesion of lip
C00.8  Lip, NOS

C00.8  Overlapping lesion of lip
C00.
9  Lip, NOS

2/10/2017

19

Appendix - Carcinoma

WHO Classification of Tumors

238

1

8073 Squamous cell carcinoma

8070 Squamous cell carcinoma, NOS

12/9/2016

55

Ovary, Fallopian Tube and Primary Peritoneal Carcinoma

WHO Classification of Tumors

682

1

8260 Adult granulosa cell tumor

8620 Adult granulosa cell tumor

12/9/2016

55

Ovary, Fallopian Tube and Primary Peritoneal Carcinoma

WHO Classification of Tumors

682

1

8542 Solid pseudopapillary neoplasm

8452 Solid pseudopapillary neoplasm

12/9/2016

55

Ovary, Fallopian Tube and Primary Peritoneal Carcinoma

WHO Classification of Tumors

682

1

8960 Paraganglioma

8960 Wilms tumor

12/9/2016

55

Ovary, Fallopian Tube and Primary Peritoneal Carcinoma

WHO Classification of Tumors

682

1

8963 Extra-gastrointestinal stromal tumor

8936 Extra-gastrointestinal stromal tumor

12/9/2016

38

Bone

WHO Classification of Tumors

472

2

8540 Malignant peripheral nerve sheath tumor

9540 Malignant peripheral nerve sheath tumor

11/18/2016

73

Thyroid - Differentiated and Anaplastic

WHO Classification of Tumors

874

1

Code omitted

8260 Papillary carcinoma of the thyroid

11/18/2016

73

Thyroid - Differentiated and Anaplastic

WHO Classification of Tumors

874

1

8050 Papillary carcinoma

8050 Papillary carcinoma, NOS

11/11/2016

12

Nasal Cavity and Paranasal Sinuses

WHO Classification of Tumors

138

1

8429 Atypical Carcinoid

8249 Atypical Carcinoid

(top of page)

Clarification 

Date Posted

Chapter or Part Number

Chapter or Part Title

Section

Page Number

Column Number

Before Correction

After Correction

6/16/2017

73

Thyroid - Differentiated and Anaplastic

Pathological Classification

878

2

For staging purposes, “any N” includes pN0, pN1, pNX, cN0, or cN1 disease....lymph nodes to be sampled, pathological confirmation of one or more benign lymph nodes mandates a pN0 designation.

For staging purposes, “any N” includes pN0, pN1, pNX, cN0, or cN1 disease....lymph nodes to be sampled, pathological confirmation of one or more benign lymph nodes mandates a pN0 designation.

The identification of psammomatous calcifications within a cervical lymph node is considered metastatic disease and should be classified as N1 disease.

6/16/2017

73

Thyroid - Differentiated and Anaplastic

Pathological Classification

878

2

However gross extrathyroidal extension that can be identified clearly by imaging or intraoperative findings is classified as T3b disease…mediastinal vessels).

However gross extrathyroidal extension that can be identified clearly by imaging, intraoperative findings, or examination of tumor specimens is classified as T3b disease…mediastinal vessels).

1/6/2017

5

Staging Head and Neck Cancers

Pathological N (pN)

61

1

N2c: Metastasis in bilateral or contralateral lymph nodes, none larger than 6 cm in greatest dimension and ENE(−)

N2c: Metastasis in bilateral or contralateral lymph node(s), none larger than 6 cm in greatest dimension and ENE(−)

1/6/2017

5

Staging Head and Neck Cancers

Pathological N (pN)

61

1

N2: Metastasis in a single ipsilateral lymph node, 3 cm or smaller in greatest dimension and ENE(+);
or larger than 3 cm but not larger than 6 cm in greatest dimension and ENE(−);
or metastases in multiple ipsilateral lymph nodes, none larger than 6 cm in greatest dimension and ENE(−);
or in bilateral or contralateral lymph nodes, none larger than 6 cm in greatest dimension, ENE(−)

N2: Metastasis in a single ipsilateral lymph node, 3 cm or smaller in greatest dimension and ENE(+);
or larger than 3 cm but not larger than 6 cm in greatest dimension and ENE(−);
or metastases in multiple ipsilateral lymph nodes, none larger than 6 cm in greatest dimension and ENE(−);
or in bilateral or contralateral lymph node
(s), none larger than 6 cm in greatest dimension, ENE(−)

1/6/2017

6

Cervical Lymph Nodes and Unknown Primary Tumors of the Head and Neck

Pathological N (pN)

75

1

N2c: Metastasis in bilateral or contralateral lymph nodes, none larger than 6 cm in greatest dimension and ENE(−)

N2c: Metastasis in bilateral or contralateral lymph node(s), none larger than 6 cm in greatest dimension and ENE(−)

1/6/2017

7

Lip and Oral Cavity

Pathological N (pN)

91

1

N2: Metastasis in a single ipsilateral lymph node, 3 cm or smaller in greatest dimension and ENE(+);
or larger than 3 cm but not larger than 6 cm in greatest dimension and ENE(−);
or metastases in multiple ipsilateral lymph nodes, none larger than 6 cm in greatest dimension and ENE(−);
or in bilateral or contralateral lymph nodes, none larger than 6 cm in greatest dimension, ENE(−)

N2: Metastasis in a single ipsilateral lymph node, 3 cm or smaller in greatest dimension and ENE(+);
or larger than 3 cm but not larger than 6 cm in greatest dimension and ENE(−);
or metastases in multiple ipsilateral lymph nodes, none larger than 6 cm in greatest dimension and ENE(−);
or in bilateral or contralateral lymph node
(s), none larger than 6 cm in greatest dimension, ENE(−)

1/6/2017

7

Lip and Oral Cavity

Pathological N (pN)

91

1

N2c: Metastasis in bilateral or contralateral lymph nodes, none larger than 6 cm in greatest dimension and ENE(−)

N2c: Metastasis in bilateral or contralateral lymph node(s), none larger than 6 cm in greatest dimension and ENE(−)

1/6/2017

8

Major Salivary Glands

Pathological N (pN)

100

1

N2: Metastasis in a single ipsilateral lymph node, 3 cm or smaller in greatest dimension and ENE(+);
or larger than 3 cm but not larger than 6 cm in greatest dimension and ENE(−);
or metastases in multiple ipsilateral lymph nodes, none larger than 6 cm in greatest dimension and ENE(−);
or in bilateral or contralateral lymph nodes, none larger than 6 cm in greatest dimension, ENE(−)

N2: Metastasis in a single ipsilateral lymph node, 3 cm or smaller in greatest dimension and ENE(+);
or larger than 3 cm but not larger than 6 cm in greatest dimension and ENE(−);
or metastases in multiple ipsilateral lymph nodes, none larger than 6 cm in greatest dimension and ENE(−);
or in bilateral or contralateral lymph node
(s), none larger than 6 cm in greatest dimension, ENE(−)

1/6/2017

11

Oropharynx (p16-) and Hypopharynx

Pathological N (pN)

129

2

N2: Metastasis in a single ipsilateral lymph node, 3 cm or smaller in greatest dimension and ENE(+);
or larger than 3 cm but not larger than 6 cm in greatest dimension and ENE(−);
or metastases in multiple ipsilateral lymph nodes, none larger than 6 cm in greatest dimension and ENE(−);
or in bilateral or contralateral lymph nodes, none larger than 6 cm in greatest dimension, ENE(−)

N2: Metastasis in a single ipsilateral lymph node, 3 cm or smaller in greatest dimension and ENE(+);
or larger than 3 cm but not larger than 6 cm in greatest dimension and ENE(−);
or metastases in multiple ipsilateral lymph nodes, none larger than 6 cm in greatest dimension and ENE(−);
or in bilateral or contralateral lymph node
(s), none larger than 6 cm in greatest dimension, ENE(−)

1/6/2017

11

Oropharynx (p16-) and Hypopharynx

Pathological N (pN)

129

2

N2c: Metastasis in bilateral or contralateral lymph nodes, none larger than 6 cm in greatest dimension and ENE(−)

N2c: Metastasis in bilateral or contralateral lymph node(s), none larger than 6 cm in greatest dimension and ENE(−)

1/6/2017

12

Nasal Cavity and Paranasal Sinuses

Pathological N (pN)

143

1

N2: Metastasis in a single ipsilateral lymph node, 3 cm or smaller in greatest dimension and ENE(+);
or larger than 3 cm but not larger than 6 cm in greatest dimension and ENE(−);
or metastases in multiple ipsilateral lymph nodes, none larger than 6 cm in greatest dimension and ENE(−);
or in bilateral or contralateral lymph nodes, none larger than 6 cm in greatest dimension, ENE(−)

N2: Metastasis in a single ipsilateral lymph node, 3 cm or smaller in greatest dimension and ENE(+);
or larger than 3 cm but not larger than 6 cm in greatest dimension and ENE(−);
or metastases in multiple ipsilateral lymph nodes, none larger than 6 cm in greatest dimension and ENE(−);
or in bilateral or contralateral lymph node
(s), none larger than 6 cm in greatest dimension, ENE(−)

1/6/2017

12

Nasal Cavity and Paranasal Sinuses

Pathological N (pN)

143

1

N2c: Metastasis in bilateral or contralateral lymph nodes, none larger than 6 cm in greatest dimension and ENE(−)

N2c: Metastasis in bilateral or contralateral lymph node(s), none larger than 6 cm in greatest dimension and ENE(−)

1/6/2017

13

Larynx

Pathological N (pN)

156

1

N2c: Metastasis in bilateral or contralateral lymph nodes, none larger than 6 cm in greatest dimension and ENE(−)

N2c: Metastasis in bilateral or contralateral lymph node(s), none larger than 6 cm in greatest dimension and ENE(−)

1/6/2017

15

Cutaneous Squamous Cell Carcinoma of the Head and Neck

Pathological N (pN)

178

2

N2: Metastasis in a single ipsilateral lymph node, 3 cm or smaller in greatest dimension and ENE(+);
or larger than 3 cm but not larger than 6 cm in greatest dimension and ENE(−);
or metastases in multiple ipsilateral lymph nodes, none larger than 6 cm in greatest dimension and ENE(−);
or in bilateral or contralateral lymph nodes, none larger than 6 cm in greatest dimension, ENE(−)

N2: Metastasis in a single ipsilateral lymph node, 3 cm or smaller in greatest dimension and ENE(+);
or larger than 3 cm but not larger than 6 cm in greatest dimension and ENE(−);
or metastases in multiple ipsilateral lymph nodes, none larger than 6 cm in greatest dimension and ENE(−);
or in bilateral or contralateral lymph node
(s), none larger than 6 cm in greatest dimension, ENE(−)

1/6/2017

15

Cutaneous Squamous Cell Carcinoma of the Head and Neck

Pathological N (pN)

178

2

N2c: Metastasis in bilateral or contralateral lymph nodes, none larger than 6 cm in greatest dimension and ENE(−)

N2c: Metastasis in bilateral or contralateral lymph node(s), none larger than 6 cm in greatest dimension and ENE(−)

1/6/2017

7

Lip and Oral Cavity

Mucosal Lip

81

2

The remainder of the vermillion is staged using the skin chapter (Chapter 47).

The remainder of the vermillion is stage using the chapter on cutaneous squamous cell carcinoma of the head and neck (Chapter 15).

12/9/2016

7

Lip and Oral Cavity

Rules for Classification > Pathological Classification > Pathological assessment of ENE

85

1

Only ENEma is used to define pathological ENE(+) nodal status

ENEmi and ENEma are used to define pathological ENE(+) nodal status

12/9/2016

7

Lip and Oral Cavity

Prognostic Factors > Additional Factors Recommended for Clinical Care > Extranodal Extension

85

1

Only ENEma is used to define pathological ENE nodal status (Fig. 7.5). ENEmi versus ENEn will not affect current nodal staging, but data collection is recommended to allow standardization of data collection and future analysis.

ENEmi and ENEma are used to define pathological ENE nodal status (Fig. 7.5). ENEmi versus ENEn will affect current nodal staging, and data collection is recommended to allow standardization of data collection and future analysis.

12/9/2016

16

Esophagus and Esophagogastric Junction

Anatomy

187

n/a

Table 16.1 Primary site of esophageal cancer based on proximal edge of tumor

Table 16.1 Anatomy of esophageal cancer primary site by ICD-O-3 topography codes

12/2/2016

74

Thyroid - Medullary

Prognostic Factors / Additional Factors Recommended for Clinical Care

896

2

Incorrect heading: Sporadic or Medullary MTC

Sporadic or Hereditary MTC

10/28/2016

73

Thyroid - Differentiated and Anaplastic

Imaging

877

2

Most patients will be clinical MX, as routine use of cross-sectional or functional (RAI)…

Most patients will be clinical M0, as routine use of cross-sectional or functional (RAI)…

(top of page)

Omission​

Date Posted

Chapter or Part Number

Chapter or Part Title

Section

Page Number

Column Number

Before Correction

After Correction

5/19/2017

50

Vulva

Author List

633

n/a

…Alexander B. Olawaiye, Lee-may Chen…

…Alexander B. Olawaiye, Priya R. Bhosale, Lee-may Chen…

5/19/2017

51

Vagina

Author List

641

n/a

…Alexander B. Olawaiye, Lee-may Chen…

…Alexander B. Olawaiye, Priya R. Bhosale, Lee-may Chen…

5/19/2017

52

Cervix Uteri

Author List

649

n/a

…Adriana Bermudez, Edward C. Grendys…

…Adriana Bermudez, Priya R. Bhosale, Edward C. Grendys…

5/19/2017

53

Corpus Uteri - Carcinoma and Carcinosarcoma

Author List

661

n/a

…Adriana Bermudez, Perry W. Grigsby…

…Adriana Bermudez, Priya R. Bhosale, Perry W. Grigsby

5/19/2017

54

Corpus Uteri - Sarcoma

Author List

671

n/a

…Alexander B. Olawaiye, Robert K. Brookland…

…Alexander B. Olawaiye, Priya R. Bhosale, Robert K. Brookland…

5/19/2017

55

Ovary, Fallopian Tube and Primary Peritoneal Carcinoma

Author List

681

n/a

…Adriana Bermudez, Lee-may Chen…

…Adriana Bermudez, Priya R. Bhosale, Lee-may Chen…

2/3/2017

82

Plasma Cell Myeloma and Plasma Cell Disorders

Author List

973

n/a

P. Leif Bergsagel, Elaine S. Jaffe, John P. Leonard

P. Leif Bergsagel, Vincent Rajkumar, Ola Landgren, Michael M. Graham, Joseph Khoury, Elaine S. Jaffe, John P. Leonard

11/4/2016

II

Head and Neck

Members of the Head and Neck Expert Panel

53

1

Panel member name omitted

Shirley Jordan Seay, PhD, OCN, CTR - Data Collection Core Representative

10/28/2016

52

Cervix Uteri

Author List

649

n/a

…Ian S. Hagemann, Esther Oliva, Lorraine Portelance…

…Ian S. Hageman, Lorraine Portelance…

10/28/2016

54

Corpus Uteri - Sarcoma

Author List

671

n/a

…Ian S. Hagemann, Matthew A. Powell…

...Ian S. Hagemann, Esther Oliva, Matthew A. Powell…

​​​​​​​(top of page)

​​​​